CLINICAL_TRIALS
ClinicalTrials.gov record update
A Feasibility Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT06066138
- Title field or adapter rule
- {'original_value': 'A Feasibility Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing', 'source_field': 'protocolSection.identificationModule.officialTitle'}
- Ingested At
- 2026-10-31T23:27:36.718162+00:00
- Published At
- 2026-10-16T00:00:00+00:00
- Record Updated At
- 2026-10-16
- Source Retrieved At
- 2026-10-31T22:19:02.163121+00:00
- Timestamp Basis
- ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
- Date limitation
- ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Locally Advanced Alveolar Soft Part Sarcoma", "Metastatic Alveolar Soft Part Sarcoma", "Locally Advanced Non Small Cell Lung Cancer", "Metastatic Non Small Cell Lung Cancer", "Locally Advanced Small Cell Lung Cancer", "Metastatic Small Cell Lung Cancer", "Locally Advanced Hepatocellular Carcinoma", "Metastatic Hepatocellular Carcinoma", "Locally Advanced Melanoma", "Metastatic Melanoma"]- protocolSection.statusModule.lastUpdatePostDateStruct
{"date": "2026-10-16", "type": "ACTUAL"}- protocolSection.identificationModule.nctId
"NCT06066138"- protocolSection.identificationModule.officialTitle
"A Feasibility Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct
null
Study condition terms
Interventions recorded in this study
- {'armGroupLabels': ['Arm 1'], 'description': 'Atezolizumab administered via IV at either 1,200 mg q3 weeks, or 1,680 mg q4 weeks for the first 2 doses followed by 840mg q2 weeks or q6 weeks.', 'name': 'Atezolizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
An intervention appearing in a study record does not establish an effect or an approved use.
Drug names recorded in this source
A recorded drug name is not by itself an indication or a condition-specific relationship.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.